Sitagliptin (Januvia) - Diabetes guide

Sitagliptin's transition from brand-only availability to a generic market represents a significant change in accessibility for patients with type 2 diabetes who have been managing costs of brand-name Januvia. Generic sitagliptin entered the market after patent protection expired, and multiple manufacturers have received or are seeking FDA approval to produce and distribute their own generic formulations. FDA bioequivalence requirements for generic sitagliptin follow the same standards applied to all generic drugs. Each manufacturer must demonstrate that their tablet formulation delivers the active drug at equivalent blood concentration levels and absorption rate as the Januvia reference product. For sitagliptin, a well-characterized small molecule, bioequivalence testing is methodologically straightforward and the field has accumulated reliable data from generic approval submissions. The available doses of sitagliptin tablets, including 25 mg, 50 mg, and 100 mg strengths, each require individual bioequivalence demonstration for each strength. Manufacturers that have received approval have demonstrated this equivalence across the approved dose range. Tablet appearance differences between brand Januvia and generic sitagliptin, or between different generic manufacturers, are expected and normal. The FDA requires therapeutic equivalence of the active compound, not physical uniformity of the tablet or capsule. Differences in tablet color, coating, or inactive ingredients like fillers and binders do not indicate a difference in the drug's effect. Patients who have been stable on brand Januvia and are switched to generic sitagliptin may initially be alert to whether their glucose control remains similar after the transition. Hemoglobin A1C checks at regular intervals as part of routine diabetes monitoring will confirm whether glycemic targets are maintained. Any clinically meaningful change in control should be evaluated with the provider as a clinical matter rather than assumed to be a generic substitution effect. Fixed-dose combination products containing sitagliptin, such as the sitagliptin-metformin combination, also have generic versions available. These products carry the same bioequivalence requirements and provide a lower-cost option for patients on both components. The availability of generic sitagliptin expands the patient population who can realistically maintain long-term DPP-4 inhibitor therapy, as cost barriers that existed during brand exclusivity are progressively reduced. This improved access matters for adherence and long-term glycemic management outcomes. For patients who want to understand what the move to generic means for their sitagliptin prescription, reviewing information about generic januvia-sitagliptin reliability provides a useful overview for confident therapy continuation. For patients comparing the DPP-4 inhibitor class to other diabetes medications and evaluating generic options across the category, the resources at diabetes medication category and patient guides offer valuable context.

Understanding Prazosin Pricing and How Patients Access It Affordably

Prazosin has been available as a generic medication in the United States for several decades. With patent protection long expired and multiple manufacturers producing the capsule form, pricing for prazosin is consistently among the most accessible in the antihypertensive category. Patients who understand their pricing options can reliably obtain this medication without significant financial burden. Brand-name Minipress is rarely dispensed today because generic prazosin has displaced it in nearly all pharmacy settings. Generic capsules are available in 1 mg and 2 mg strengths and cover the full therapeutic range for both hypertension and PTSD nightmare management. The clinical equivalence of generic prazosin to the original brand is well established. At most retail pharmacies in the United States, a 30-day supply of prazosin costs between approximately five and fifteen dollars when purchased without insurance. This range reflects standard competitive generic pricing and does not require any special program or discount card. Prescription discount programs available through pharmacy benefit aggregators provide access to reduced pricing at major and independent pharmacies. Presenting a discount card along with a prescription at the pharmacy counter often results in pricing at the lower end of the generic range. These programs are free to use and require no enrollment process. Patients with Medicaid coverage typically receive prazosin with little or no cost sharing because it is included on virtually every public formulary. Medicare Part D plans almost universally place generic prazosin in their lowest cost tiers, resulting in minimal patient copays for most enrollees. Private insurance plans vary in their tier placement for generic medications, but prazosin's status as an older, low-cost generic means it almost always falls in the first or second cost tier. Patients who face unexpectedly high copays from their insurer can verify whether an independent pharmacy purchase using a discount program would be less expensive than their insurance copay. The combination of decades of generic availability, multiple manufacturers, and consistent competition among pharmacy chains keeps prazosin among the most stably priced generic antihypertensives available. Price spikes that occasionally affect some generic medications have not characterized prazosin's availability. For a full review of available options including where to compare costs for this medication, explore prazosin pricing options and learn about accessible paths to treatment. For patients evaluating the broader landscape of blood pressure medications and their associated costs, blood pressure category medication guides provides comparative context across the antihypertensive class.

We Will Miss Antibiotics When They’re Gone

By www.nytimes.com

On Friday, the Centers for Disease Control and Prevention released a disturbing report about the death of an elderly woman in Washoe County, Nev. What killed her wasn’t heart disease, cancer or pneumonia. What killed her were bacteria that were resistant to every antibiotic doctors could throw at them.

This anonymous woman is only the latest casualty in a war against antibiotic-resistant bacteria — a war that we are losing. Although most bacteria die when they encounter an antibiotic, a few hardy bugs survive. Through repeated exposure, those tough bacteria proliferate, spreading resistance genes through the bacterial population. That’s the curse of antibiotics: The more they’re used, the worse they get, especially when they’re used carelessly.

Already, more than 23,000 people in the United States are estimated to die every year from resistant bacteria. That death toll will grow as microbes develop new mechanisms to defeat the drugs that, for decades, have kept infections at bay. We are on the cusp of what the World Health Organization calls a “post-antibiotic era.”

And we will miss antibiotics when they’re gone. Minor scrapes and routine infections could become life threatening. Common surgeries would start looking like Russian roulette. Gonorrhea and other sexually transmitted infections might become untreatable. Diseases that our parents defeated — like tuberculosis — could come roaring back. The economic costs would be staggering: In September, the World Bank estimated that between 1.1 and 3.8 percent of the global economy will be lost by 2050 if we fail to act.

Yet few new antibiotics are in development. Most large drug companies have fled the field. The reason is simple: To conserve their effectiveness, new antibiotics are put on the shelf to be used only when older antibiotics stop working. That makes perfect sense for public health, but companies can’t make a profit on what they can’t sell. This mismatch between the huge social value of new antibiotics and the relative indifference of drug manufacturers could spell disaster.

Aware of the problem, Congress has taken some initial steps to address it. In particular, the 2012 Generating Antibiotic Incentives Now Act grants to manufacturers an extended, exclusive period to sell newly approved antibiotics. By keeping generics off the market for longer, Congress hoped to sweeten the pot for manufacturers and encourage needed research.

But the law probably won’t stimulate much innovation. A couple more years of poor sales are a small incentive and may actually promote overuse of antibiotics. The law is also poorly targeted. Some “new” antibiotics are similar to existing compounds — so similar that bacteria are already resistant to them. We don’t need to reward manufacturers for tweaking antibiotics that we already have. We need them to develop entirely new antibiotics.

A few federal agencies have shown more initiative. Medicare, for example, has moved to require hospitals and nursing homes to adopt plans to prevent the spread of drug-resistant infections and to assure the proper use of antibiotics. The Centers for Disease Control and Prevention is taking steps to limit the spread of resistant infections and to reduce unnecessary use of antibiotics. The Food and Drug Administration has simplified approval standards and has worked with industry to limit the use of antibiotics in livestock, which today accounts for three-quarters of antibiotic sales in the United States. And the Biomedical Advanced Research and Development Authority has been working creatively to build public-private partnerships to support the most promising research.

But Congress needs to think bigger if it wants to fix the broken antibiotic business model. Although the patent system is good at producing new blood-pressure medications and cardiovascular drugs, it’s not the right fit for antibiotics. Because new antibiotics may be held in reserve for years, manufacturers can’t sell enough during the patent term to justify large research investments. Congress should instead reward manufacturers that bring a targeted, highly innovative antibiotic to market with a substantial financial prize; in exchange, manufacturers would surrender their patent.

This kind of “market-entry” reward would enable public health officials and physicians to deploy new drugs precisely where they’re needed. Manufacturers would no longer have an incentive to milk their patent, marketing the drug for inappropriate uses. The antibiotic could also be sold at a reasonable price in developing countries, which might otherwise be unable to afford a patented antibiotic.

Financing market-entry rewards would be expensive, perhaps $4 billion per year in total, or about 10 percent of the annual global bill for antibiotics. But you can’t defeat bacteria on the cheap. They’ve survived for billions of years because they’re so good at adapting to new threats. Staying one step ahead will require ingenuity, money and radical change. Tinkering around the margins isn’t going to cut it.

Source: https://www.nytimes.com/2017/01/18/opinion/how-to-avoid-a-post-antibiotic-world.html?_r=0

http://antibio.xyz/gantrisin/